Skip to content

Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia

Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06668298
Enrollment
150
Registered
2024-10-31
Start date
2024-11-30
Completion date
2025-06-30
Last updated
2024-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Old Age

Keywords

old age, knee arthroplasty, pain

Brief summary

Traditional opioid analgesia is a treatment method for moderate to severe pain. However, the use of opioid drugs is not without risks. When treating acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability, and itching. The purpose of this study is to evaluate the comparison of G protein biased μ - opioid receptor agonist oliceridine and traditional μ - opioid receptor agonist sufentanil in terms of analgesia in patients under general anesthesia.

Detailed description

All patients who met the inclusion criteria were randomly divided into two groups based on the use of postoperative analgesic pumps: the sufentanil group and the oliceridine group. The sufentanil group received a treatment regimen of sufentanil 2 µ g · kg-1; The treatment regimen for the oliceridine group is oliceridine 0.4mg · kg-1. The main postoperative observation indicator is the measurement of total pain intensity difference within 48 hours (SPID-48).

Interventions

The formula for postoperative analgesia pump is oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.

The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.

Sponsors

Henan Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

All patients who met the inclusion criteria were randomly divided into two groups based on the use of postoperative analgesic pumps: the sufentanil group and the oliceridine group. The sufentanil group received a treatment regimen of sufentanil 2 µ g · kg-1; The treatment regimen for the oliceridine group is oliceridine 0.4mg · kg-1.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age\>65 years old 2. ASA Level I-III 3. BMI 18.5-29.9 4. Patients undergoing knee joint surface replacement surgery under general anesthesia 5. Postoperative Patient Controlled Intravenous Analgesia Pump (PCIA) Treatment 6. Possess reading and writing abilities 7. You can sign an informed consent form

Exclusion criteria

1. Suffering from chronic pain or mental illness before surgery 2. Unable to communicate due to cognitive impairment or language barriers before surgery 3. Patients who have used opioid drugs three days before surgery 4. Patients with long-term alcohol consumption 5. Abnormal liver and kidney function or dialysis patients 6. Concurrent severe cardiovascular, respiratory, and autonomic neuropathy 7. Participated in clinical studies of other drugs or medical devices in the past 3 months

Design outcomes

Primary

MeasureTime frameDescription
Measurement of Total Pain Intensity Difference within 48 Hours (SPID-48)48hourPostoperative pain was evaluated using the NRS Pain Digital Rating Scale at 1, 6, 12, 24, 36, and 48 hours post surgery; Multiply the difference in pain intensity at each post baseline time point within 48 hours (subtracting the pain intensity at a specific post baseline time point from the pain intensity at baseline) by the duration (in hours) of the previous time point, and then add them up.

Secondary

MeasureTime frameDescription
Adverse reactions48hourIncidence of nausea, vomiting, dizziness, headache, constipation, itching, and hypoxia

Contacts

Primary ContactNingning Fu
736508728@qq.com8618790658707
Backup ContactJiaqiang Zhang
Jiaqiang197628@163.com8613937121360

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026